Laboratório de Biologia Molecular, Instituto de Biociências, Departamento de Biologia Geral e Aplicada, Universidade Estadual Paulista "Júlio de Mesquita Filho" - Campus Rio Claro, Rio Claro, SP, 13506-900, Brazil.
Instituto de Biociência, Centro de Estudos de Insetos Sociais, Universidade Estadual Paulista "Júlio de Mesquita Filho", Rio Claro, SP, Brazil.
Mol Biol Rep. 2021 Apr;48(4):3463-3474. doi: 10.1007/s11033-021-06364-3. Epub 2021 Apr 28.
Hepatocellular carcinoma is one of the most common types of cancer in the world with high mortality rate and new therapies that control of fatty acid metabolism may limit the proliferation of cancer cells. In the last two decades, the non-coding RNAs have been considered as promising molecular tools to treat diseases, because they are able to modulate gene expression and the metabolic routes; however, deep investigation of their mechanistic behavior in pathologies must be performed. Thus, our aim was to evaluate the modulatory effect of the miR-1914-5p in controlling lipid metabolism in HepG2, a widely used human hepatocarcinoma cell line. The molecular and cellular analyses demonstrated that the functional inhibition of the investigated microRNA completely changed the cellular metabolism and behavior, compared to control groups. The in vitro inhibition of the miR-1914-5p increased the energy expenditure pointed in different analyses, decreasing cell doubling time and migration rate verified in wound healing and in the classical transwell chambers invasion assays, which makes the miR-1914-5p a candidate for further translational and preclinical studies to validate its function in controlling metastasis in liver cancer or even treat those diseases.
肝细胞癌是世界上最常见的癌症类型之一,死亡率很高,新的脂肪酸代谢控制疗法可能会限制癌细胞的增殖。在过去的二十年中,非编码 RNA 被认为是治疗疾病的有前途的分子工具,因为它们能够调节基因表达和代谢途径;然而,必须对它们在病理中的机制行为进行深入研究。因此,我们的目的是评估 miR-1914-5p 在控制 HepG2(一种广泛使用的人肝癌细胞系)中脂质代谢方面的调节作用。分子和细胞分析表明,与对照组相比,被研究的 microRNA 的功能抑制完全改变了细胞代谢和行为。体外抑制 miR-1914-5p 增加了不同分析中的能量消耗,通过划痕愈合和经典的 Transwell 室侵袭实验验证了细胞倍增时间和迁移率的降低,这使得 miR-1914-5p 成为进一步转化和临床前研究的候选物,以验证其在控制肝癌转移或治疗这些疾病中的功能。